Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Curadev Pharma Private Limited","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$270.4 million ","upfrontCash":"Undisclosed","newsHeadline":"Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Curadev Pharma Private Limited"}]

Curadev Pharma Private Limited

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bayer and Curadev Sign Research Collaboration and License Agreement to Develop novel STING Antagonists Across Indications

Details:

The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: $270.4 million Upfront Cash: Undisclosed

Deal Type: Collaboration March 23, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY